| ［1］ |
Cardoso F，Spence D， Mertz S， et al. Global analysis of advanced/metastatic breast cancer： decade report （2005 - 2015）［J］. Breast，2018， 39： 131-138.
|
| ［2］ |
Anderson WF， Rosenberg PS， Katki HA. Tracking and evaluating molecular tumor markers with cancer registry data： HER2 and breast cancer［J］. J Natl Cancer Inst， 2014， 106（5）： dju093.
|
| ［3］ |
Reinbolt RE， Mangini N， Hill JL， et al. Endocrine therapy in breast cancer： the neoadjuvant， adjuvant， and metastatic approach［J］. Semin Oncol Nurs， 2015， 31（2）： 146-155.
|
| ［4］ |
Kwapisz D. Cyclin-dependent kinase 4/6 inhibitors in breast cancer：palbociclib， ribociclib， and abemaciclib［J］. Breast Cancer Res Treat，2017， 166（1）： 41-54.
|
| ［5］ |
Goel S， Bergholz JS， Zhao JJ. Targeting CDK4 and CDK6 in cancer［J］. Nat Rev Cancer， 2022， 22（6）： 356-372.
|
| ［6］ |
Savard MF， Khan O， Hunt KK， et al. Redrawing the lines： the next generation of treatment in metastatic breast cancer［J］. Am Soc Clin Oncol Educ Book， 2019， 39： e8-e21.
|
| ［7］ |
Goetz MP， Toi M， Campone M， et al. MONARCH 3： abemaciclib as initial therapy for advanced breast cancer［J］. JCO， 2017， 35（32）：3638-3646.
|
| ［8］ |
Sledge GW， Toi M， Neven P， et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive， ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2： a randomized clinical Trial［J］. JAMA Oncol，2020，6（1）：116-124.
|
| ［9］ |
Rugo HS， Huober J， García-Sáenz JA， et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive， human epidermal growth factor receptor 2-negative advanced breast cancer： safety analysis of MONARCH 2 and MONARCH 3［J］. Oncologist， 2021， 26（1）： e53-e65.
|
| ［10］ |
Johnston SRD， Harbeck N， Hegg R， et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR＋， HER2-， nodepositive， high-risk， early breast cancer （monarchE）［J］. JCO， 2020，38（34）： 3987-3998.
|
| ［11］ |
Zhang J， Yang N， Ji D， et al. A randomized phase I study of abemaciclib in Chinese patients with advanced and/or metastatic cancers［J］. Target Oncol， 2021， 16（2）： 177-187.
|
| ［12］ |
Fujiwara Y， Tamura K， Kondo S， et al. Phase 1 study of abemaciclib，an inhibitor of CDK 4 and 6， as a single agent for Japanese patients with advanced cancer［J］. Cancer Chemother Pharmacol， 2016， 78（2）： 281-288.
|
| ［13］ |
Ren X， Yan C，Tian L，et al. Haematopoietic cytopenia associated with cyclin-dependent kinase 4/6 inhibitors： a real-world study of data from the food and drug administration adverse event reporting system database ［ J ］. Int J Immunopathol Pharmacol， 2022， 36：3946320221145520.
|
| ［14］ |
Sammons SL， Topping DL， Blackwell KL. HR ＋， HER2- advanced breast cancer and CDK4/6 inhibitors：mode of action，clinical activity，and safety Profiles［J］. Curr Cancer Drug Targets，2017，17（7）：637-649.
|
| ［15］ |
Piezzo M， Cocco S， Caputo R， et al. Targeting cell cycle in breast cancer： CDK4/6 inhibitors［J］. IJMS， 2020， 21（18）： 6479.
|
| ［16］ |
Braal CL， Jongbloed EM， Wilting SM， et al. Inhibiting CDK4/6 in breast cancer with palbociclib，ribociclib，and abemaciclib：similarities and differences［J］. Drugs， 2021， 81（3）： 317-331.
|
| ［17］ |
George MA， Qureshi S， Omene C， et al. Clinical and pharmacologic differences of CDK4/6 inhibitors in breast cancer［J］. Front Oncol，2021， 11： 693104.
|
| ［18］ |
Petrelli F， Ghidini A， Pedersini R， et al. Comparative efficacy of palbociclib， ribociclib and abemaciclib for ER ＋ metastatic breast cancer：an adjusted indirect analysis of randomized controlled trials［J］.Breast Cancer Res Treat， 2019， 174（3）： 597-604.
|
| ［19］ |
Cristofanilli M， Turner NC， Bondarenko I， et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormonereceptor-positive， HER2-negative metastatic breast cancer that progressed on previous endocrine therapy （PALOMA-3）： final analysis of the multicentre， double-blind， phase 3 randomised controlled trial［J］. Lancet Oncol， 2016， 17（4）： 425-439.
|
| ［20］ |
O’Shaughnessy J， Petrakova K， Sonke GS， et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR＋， HER2-advanced breast cancer in the randomized MONALEESA-2 trial［J］.Breast Cancer Res Treat， 2018， 168（1）： 127-134.
|
| ［21］ |
Tamura K. Differences of cyclin-dependent kinase 4/6 inhibitor，palbociclib and abemaciclib， in breast cancer［J］. Jpn J Clin Oncol，2019， 49（11）： 993-998.
|
| ［22］ |
Sledge GW， Toi M， Neven P， et al. MONARCH 2： abemaciclib in combination with fulvestrant in women with HR ＋/HER2- advanced breast cancer who had progressed while receiving endocrine therapy［J］.J Clin Oncol， 2017， 35（25）： 2875-2884.
|
| ［23］ |
Rugo HS， O’Shaughnessy J， Boyle F， et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer：safety and patient-reported outcomes from the monarchE study［J］. Ann Oncol， 2022， 33（6）： 616-627.
|
| ［24］ |
Modi ND， Abuhelwa AY， Badaoui S， et al. Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib［J］. The Breast， 2021， 58： 57-62.
|
| ［25］ |
Chigutsa E， Kambhampati SRP， Karen Sykes A， et al. Development and application of a mechanistic population modeling approach to describe abemaciclib pharmacokinetics［J］. CPT Pharmacometrics Syst Pharmacol， 2020， 9（9）： 523-533.
|
| ［26］ |
Goetz MP， Okera M， Wildiers H， et al. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer： an age-specific subgroup analysis of MONARCH 2 and 3 trials ［J］. Breast Cancer Res Treat， 2021，186（2）： 417-428.
|